COMMUNIQUÉS West-GlobeNewswire

NovaBridge’s Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
21/11/2025
Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 Program The ability to attract [...]
Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids
21/11/2025
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that given the high rate of non- [...]
CHRISTUS Health recognized as ‘Most Wired’ health provider for digital transformation
21/11/2025
IRVING, Texas, Nov. 20, 2025 (GLOBE NEWSWIRE) -- CHRISTUS Health has been recognized as a national 2025 “Most Wired” health provider for digital transformation that influences quality and accessibility of care for [...]
BioSyent Releases Financial Results for Q3 and YTD 2025
20/11/2025
MISSISSAUGA, Ontario, Nov. 20, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q3) and nine months (YTD) ended September 30, 2025. Key [...]
BioSyent Declares Fourth Quarter 2025 Dividend
20/11/2025
MISSISSAUGA, Ontario, Nov. 20, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.05 per common [...]
Regional Health Properties Reports Third Quarter 2025 Results Following Completion of Merger with SunLink Health Systems, Inc.
20/11/2025
ATLANTA, GA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (the “Company”, “Regional”, “we”, “us” or “our”) (OTCQB: RHEP) (OTCQB: RHEPA) (OTCQB: RHEPB) (OTCQB:RHEPZ), a self-managed healthcare real [...]
Equillium to Participate in Upcoming Investor Conferences
20/11/2025
LA JOLLA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe [...]
Information on the total number of voting rights and shares
20/11/2025
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), November 20, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on [...]
Informations sur le nombre total de droits de vote et d'actions
20/11/2025
INFORMATION RÉGLEMENTÉE Informations sur le nombre total de droits de vote et d'actions Mont-Saint-Guibert (Belgique), le 20 novembre 2025, 22:30h CET / 16:30h ET – Conformément à l'article 15 de la loi du 2 mai 2007 [...]
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
20/11/2025
BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
20/11/2025
CONSHOHOCKEN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
CapsoVision to Participate in the Benchmark 14th Annual Discovery Investor Conference
20/11/2025
Company to participate in 1:1 Investor Meetings on December 4, 2025 SARATOGA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced [...]
Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update
20/11/2025
- Alpha DaRT pancreatic cancer p atient treatments underway in U.S. multi-center pilot study - - Newly received r adioactive m aterial l icense for New Hampshire f acility positions the Company for continued advancement [...]
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome
20/11/2025
CAREFNDR underscores the potential clinical value of p altusotine b eyond acromegaly, and demonstrates progress in Crinetics’ commitment to addressing unmet needs in the neuroendocrine tumor community SAN DIEGO, Nov. 20 [...]
RxSight, Inc. to Present at the Piper Sandler Healthcare Conference
20/11/2025
ALISO VIEJO, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – November 20, 2025 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following [...]
Zevra Therapeutics, Inc. Announces CFO Transition
20/11/2025
CELEBRATION, Fla., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
PROCEPT BioRobotics® to Present at Upcoming 37th Annual Piper Sandler Healthcare Conference on December 2, 2025
20/11/2025
SAN JOSE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, [...]
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
20/11/2025
Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, [...]
Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
20/11/2025
SAN FRANCISCO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]

Pages